Dr. Reddys Laboratories has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
The XOPENEX (levalbuterol hydrochloride) inhalation solution brand and generic combined had U.S. sales of around $269.7 Million MAT for the most recent twelve months ending in June 2014.
The company's Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer.
Dr. Reddys is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
